SEC Form 4 · accession 0001246360-17-000452
NxStage Medical, Inc. · NXTM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert S. Brown
Officer — President, NxStage Kidney Care
Period of report
Feb 3, 2017
Accepted (ET)
Feb 6, 2017 · 5:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001333170
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 3, 2017 | M | 13,000 | $14.66 | A | 42,217 | D | |
| Common StockF2 | Feb 3, 2017 | S | 13,000 | $26.77 | D | 29,217 | D | |
| Common StockF3 | Feb 6, 2017 | S | 3,283 | $27.29 | D | 25,934 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $14.66 | Feb 3, 2017 | M | 13,000 | D | Apr 10, 2014 | Mar 9, 2024 | Common Stock | 13,000 | 21,958 | D |
Explanation of responses
- F1This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2016.
- F2This represents the weighted average price for shares sold in multiple transactions at prices ranging from $26.58 to $27.04, inclusive. Full information regarding the number of shares sold at each separate price within the range will be provided to NxStage Medical, Inc., any security holder of NxStage Medical, Inc. or the staff of the Securities and Exchange Commission, upon request.
- F3This represents the weighted average price for shares sold in multiple transactions at prices ranging from $27.20 to $27.43, inclusive. Full information regarding the number of shares sold at each separate price within the range will be provided to NxStage Medical, Inc., any security holder of NxStage Medical, Inc. or the staff of the Securities and Exchange Commission, upon request.